MarketPulse

platinum-resistant ovarian cancer

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Biontech Se

BioNTech Advances Late-Stage Oncology Pipeline With ASCO 2026 Clinical Data

BioNTech presents Phase 2 Pumitamig and Gotistobart survival data at ASCO 2026, advancing 25+ Phase 2/3 oncology trials including 13 registration-relevant studies.
BMYCELGrBNTXclinical trialsoncology pipeline
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Zymeworks Wins FDA Fast Track for Cancer Drug ZW191, Accelerating Path to Market

Zymeworks secures FDA Fast Track designation for ZW191, an ovarian cancer antibody-drug conjugate, accelerating development timelines.
ZYMEantibody-drug conjugatePhase 1 clinical trial